Investing.comQwen · 实盘不做把握 3/10不做原因:证据不足
北京时间·🕒 发布 22:12:34·⟳ 抓取 22:13:03 +29s·⚡ 决策 08-28 22:14:10 +1m07s·60.2 天前
Agenus 公布 botensilimab 联合 balstilimab 治疗 MSS 转移性结直肠癌 Phase 1b 临床数据：客观缓解率 21%、中位总生存 21.2 个月
Phase 1b 数据在 MSS mCRC（免疫治疗最难攻克的适应症之一）中显示出令人鼓舞的信号，但距离商业化仍有较长路径（需更大规模验证性试验）。作为微盘股，AGEN 的市值和流动性状况、合作方权益分配、以及从 Phase 1b 到注册试验的时间表均不明确。在未确认这些关键因素前，无法形成可靠的正期望交易。
📄 原文Investing.com↗ 原文
Agenus reports survival data for colorectal cancer treatment
U.S. stocks mostly flat at the open as traders await Warsh’s Jackson Hole speech LEXINGTON, Mass. - Agenus Inc. (NASDAQ…
不做 Agenus Inc.（AGEN.US）
Phase 1b 数据虽显示积极信号，但距离商业化路径长且不确定；AGEN 为微盘股，市值/流动性和合作方权益结构不明确，无法形成可靠的正期望交易。建议等待更大规模验证性试验数据或明确商业化催化后再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Agenus 公布 Phase 1b 数据显示 botensilimab+balstilimab 在重度经治 MSS mCRC 中实现 21% ORR 和 21.2 个月中位总生存，信号显著优于该适应症历史标准（MSS mCRC 通常 ORR<5%）。但 Phase 1b 仅为早期探索性数据，距离商业化需经更大规模验证性试验，且 AGEN 作为微盘股存在高波动性。合作方权益结构、市值/流动性和注册路径均不明确，无法在当前证据下形成可靠的正期望交易决策。
🔎 新鲜度:最早出现 2026-08-28 · 扩散 low · price-in 风险 low ↗
关键理由
- MSS mCRC 是免疫治疗最具挑战性的适应症之一，21% ORR 和 3 年 33% 总生存率显著优于该领域历史标准（通常 ORR<5%）
- 缓解持续时间长（中位未达到，≥37.4 个月）且不受低 TMB/无 PD-L1 表达限制，提示机制可能突破传统免疫检查点限制
- 1mg/kg 剂量疗效一致且安全性更好，为后续剂量优化和联合用药提供灵活性
主要风险
- Phase 1b 数据到注册性试验路径长且不确定，需更大规模验证性试验确认，短期无明确商业化催化
- AGEN 为微盘股，市值极小，流动性可能不足，价格波动剧烈，且合作方权益分配可能稀释股东弹性
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
未找到明确的合作/授权交易信息，但 botensilimab 管线可能已有潜在合作方，需进一步确认权益归属
检索:Agenus botensilimab partnership license deal collaboration agreement - 做多前查反向 · 来源 web · 影响 none
MSS mCRC 免疫治疗历史 ORR 通常<5%，21% 数据确实显著，但 Phase 1b 到注册试验失败率极高
检索:MSS colorectal cancer immunotherapy clinical trial failure historical ORR
先例如何影响了这次决策
对本次决策的影响:先例不足，无法为交易提供历史参考
方向:无足够先例
涨幅量级:无法校准幅度
形态:无法判断
原文全文
展开原文 · 2,086 字
U.S. stocks mostly flat at the open as traders await Warsh’s Jackson Hole speech
LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) announced the publication of Phase 1b trial results for its botensilimab and balstilimab combination therapy in heavily pretreated patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, according to a press release statement.
The study, published in Clinical Cancer Research, evaluated 123 patients who received a median of three prior lines of therapy. The treatment combination demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33%. Patients received a median of two botensilimab doses and six balstilimab doses.
The confirmed objective response rate was 21%, including three complete responses and 23 partial responses. Median duration of response was not reached, with responses extending to at least 37.4 months. Disease control rate was 69% at six weeks.
In a subgroup of 37 patients who had received a median of five prior lines of therapy, the treatment showed a 22% confirmed objective response rate, median overall survival of 16.2 months, and a three-year overall survival rate of 30%.
Exploratory biomarker analyses showed responses occurred in patients with low tumor mutational burden and no detectable PD-L1 expression. Neither biomarker was associated with response in the evaluable population.
The most common immune-mediated adverse event was diarrhea or colitis, which resolved in 98% of affected patients with a median time to resolution of 14 days. No treatment-related deaths occurred.
Efficacy was consistent across the two botensilimab dose levels evaluated, with a 21% objective response rate at both 1 mg/kg and 2 mg/kg. Lower rates of immune-mediated adverse events were observed with the 1 mg/kg dose.
The C-800-01 trial is a Phase 1b study evaluating botensilimab with or without balstilimab in patients with advanced solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) announced the publication of Phase 1b trial results for its botensilimab and balstilimab combination therapy in heavily pretreated patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, according to a press release statement.
The study, published in Clinical Cancer Research, evaluated 123 patients who received a median of three prior lines of therapy. The treatment combination demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33%. Patients received a median of two botensilimab doses and six balstilimab doses.
The confirmed objective response rate was 21%, including three complete responses and 23 partial responses. Median duration of response was not reached, with responses extending to at least 37.4 months. Disease control rate was 69% at six weeks.
In a subgroup of 37 patients who had received a median of five prior lines of therapy, the treatment showed a 22% confirmed objective response rate, median overall survival of 16.2 months, and a three-year overall survival rate of 30%.
Exploratory biomarker analyses showed responses occurred in patients with low tumor mutational burden and no detectable PD-L1 expression. Neither biomarker was associated with response in the evaluable population.
The most common immune-mediated adverse event was diarrhea or colitis, which resolved in 98% of affected patients with a median time to resolution of 14 days. No treatment-related deaths occurred.
Efficacy was consistent across the two botensilimab dose levels evaluated, with a 21% objective response rate at both 1 mg/kg and 2 mg/kg. Lower rates of immune-mediated adverse events were observed with the 1 mg/kg dose.
The C-800-01 trial is a Phase 1b study evaluating botensilimab with or without balstilimab in patients with advanced solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。